Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068421 | 0.97 | CACNA1H (0.39) | DRD2SIGMAR1CACNA1HEPHX1JAK2 | |
| SCHEMBL25755605 | 0.94 | DRD2 (0.42) | DRD2SIGMAR1CACNA1HEPHX1TDP1 | |
| SCHEMBL25755571 | 0.90 | DRD2 (0.48) | DRD2SIGMAR1CACNA1HEPHX1TDP1 | |
| SCHEMBL23765870 | 0.89 | CACNA1H (0.47) | DRD2SIGMAR1CACNA1HEPHX1TDP1 | |
| SCHEMBL25032034 | 0.85 | MEN1 (0.36) | DRD2SIGMAR1CACNA1HEPHX1TDP1 | |
| SCHEMBL25032149 | 0.83 | HRH3 (0.48) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL25755689 | 0.79 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL31305414 | 0.77 | DRD2 (0.50) | DRD2SIGMAR1CACNA1HTDP1 | |
| SCHEMBL23343285 | 0.75 | TDP1 (0.45) | EPHX1TDP1 | |
| SCHEMBL13021104 | 0.75 | DRD2 (0.46) | DRD2SIGMAR1CACNA1HTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | DRD2 3507/4885SIGMAR1 4773/4885CACNA1H 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.